AXIM Biotechnologies, Inc. (AXIM)
|Net Income (ttm)||-5.45M|
|Trading Day||January 25|
|Day's Range||0.4200 - 0.4799|
|52-Week Range||0.1 - 1.27|
AXIM® Biotechnologies Releases Preprint Manuscript Describing the Development of Company's Rapid Point-of-Care Test That Measures COVID-19 Neutralizing Antibodies
SAN DIEGO, Jan. 11, 2021 (GLOBE NEWSWIRE) -- AXIM ® Biotechnologies, Inc . (OTCQB: AXIM) (“AXIM® Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting o...
AXIM Biotechnologies is a vertically integrated research and development company focused on changing diagnosis and treatment for oncology and SARS-CoV-2 (COVID-19). The company's NeuCovix is the rapid diagnostic test measuring levels of functional neutralizing antibodies that are believed to prevent SARS-CoV-2 from entering the host cells. It is developing rapid diagnostic tests for the early detection of cancer and proprietary small molecules drugs to treat cancer and block metastasis. The company was formerly known as Axim International Inc. ... [Read more...]
John W. Huemoeller II
|Stock Exchange |
|Ticker Symbol |
In 2019, AXIM's revenue was $799,483, an increase of 308.70% compared to the previous year's $195,614. Losses were -$6.45 million, -4.55% less than in 2018.